Progress toward rubella and congenital rubella syndrome (CRS) elimination worldwide from 2012 to 2022 shows significant achievements. Rubella virus is a leading cause of vaccine-preventable birth defects, with infection during pregnancy leading to miscarriage, fetal death, stillbirth, or CRS, a range of birth defects including cataracts, deafness, heart defects, and developmental delay. A single dose of rubella-containing vaccine (RCV) provides lifelong protection. The Global Vaccine Action Plan 2011–2020 aimed to eliminate rubella in at least five of six World Health Organization (WHO) regions by 2020, and rubella elimination is a key goal of the Immunization Agenda 2030. From 2012 to 2022, the number of WHO countries including RCV in their immunization schedules increased from 132 (68%) to 175 (90%), and the percentage of infants vaccinated against rubella rose from 40% to 68%. Reported rubella cases declined by 81%, from 93,816 in 2012 to 17,407 in 2022. Verification of rubella elimination was achieved in 98 (51%) of 194 countries by 2022, up from 84 (43%) in 2019. Despite progress, approximately 25 million infants annually still lack access to RCV, mainly in low-income and conflict-affected areas. CRS surveillance has improved, with more countries conducting surveillance, leading to increased detection of cases. However, CRS cases remain a significant global burden, with over 32,000 infants born with CRS annually, primarily in countries without RCV. The elimination of rubella has been verified in 51% of countries, with 15 countries achieving elimination between 2019 and 2022. The success is attributed to high vaccine efficacy, lifelong immunity, and sustained immunization coverage. However, the threat of reintroduction remains until all countries introduce RCV. The report highlights the need for continued efforts to introduce RCV in all countries, especially those with low coverage, to achieve global rubella elimination. Challenges include data accuracy, surveillance limitations, and disruptions during the COVID-19 pandemic. Despite these, significant progress has been made, demonstrating that rubella can be eliminated even in complex socioeconomic settings.Progress toward rubella and congenital rubella syndrome (CRS) elimination worldwide from 2012 to 2022 shows significant achievements. Rubella virus is a leading cause of vaccine-preventable birth defects, with infection during pregnancy leading to miscarriage, fetal death, stillbirth, or CRS, a range of birth defects including cataracts, deafness, heart defects, and developmental delay. A single dose of rubella-containing vaccine (RCV) provides lifelong protection. The Global Vaccine Action Plan 2011–2020 aimed to eliminate rubella in at least five of six World Health Organization (WHO) regions by 2020, and rubella elimination is a key goal of the Immunization Agenda 2030. From 2012 to 2022, the number of WHO countries including RCV in their immunization schedules increased from 132 (68%) to 175 (90%), and the percentage of infants vaccinated against rubella rose from 40% to 68%. Reported rubella cases declined by 81%, from 93,816 in 2012 to 17,407 in 2022. Verification of rubella elimination was achieved in 98 (51%) of 194 countries by 2022, up from 84 (43%) in 2019. Despite progress, approximately 25 million infants annually still lack access to RCV, mainly in low-income and conflict-affected areas. CRS surveillance has improved, with more countries conducting surveillance, leading to increased detection of cases. However, CRS cases remain a significant global burden, with over 32,000 infants born with CRS annually, primarily in countries without RCV. The elimination of rubella has been verified in 51% of countries, with 15 countries achieving elimination between 2019 and 2022. The success is attributed to high vaccine efficacy, lifelong immunity, and sustained immunization coverage. However, the threat of reintroduction remains until all countries introduce RCV. The report highlights the need for continued efforts to introduce RCV in all countries, especially those with low coverage, to achieve global rubella elimination. Challenges include data accuracy, surveillance limitations, and disruptions during the COVID-19 pandemic. Despite these, significant progress has been made, demonstrating that rubella can be eliminated even in complex socioeconomic settings.